These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Expression of RANKL in breast cancer tissue in patients with fibrous dysplasia/McCune-Albright syndrome. Meier ME; Hagelstein-Rotman M; Majoor BCJ; Geels RES; Appelman-Dijkstra NM; Bravenboer N Bone; 2023 Apr; 169():116679. PubMed ID: 36652988 [TBL] [Abstract][Full Text] [Related]
4. Extent of Extraskeletal Manifestations of Fibrous Dysplasia/McCune-Albright Syndrome in Patients with Mazabraud's Syndrome. Hagelstein-Rotman M; Appelman-Dijkstra NM; Boyce AM; Chapurlat R; Dur NBJ; Gensburger D; Majoor BCJ; van de Sande MAJ; Dijkstra PDS Calcif Tissue Int; 2022 Mar; 110(3):334-340. PubMed ID: 34854944 [TBL] [Abstract][Full Text] [Related]
6. [Clinical features of Chilean patients with Fibrous Dysplasia/McCune-Albright Syndrome]. Jiménez C; Schneider P; Baudrand R; García H; Martínez A; Mendoza C; Grob F; Seiltgens C; Florenzano P Rev Med Chil; 2022 Oct; 150(10):1275-1282. PubMed ID: 37358085 [TBL] [Abstract][Full Text] [Related]
7. Improving patient outcomes in fibrous dysplasia/McCune-Albright syndrome: an international multidisciplinary workshop to inform an international partnership. Boyce AM; Turner A; Watts L; Forestier-Zhang L; Underhill A; Pinedo-Villanueva R; Monsell F; Tessaris D; Burren C; Masi L; Hamdy N; Brandi ML; Chapurlat R; Collins MT; Javaid MK Arch Osteoporos; 2017 Dec; 12(1):21. PubMed ID: 28243882 [TBL] [Abstract][Full Text] [Related]
8. A multidisciplinary care pathway improves quality of life and reduces pain in patients with fibrous dysplasia/McCune-Albright syndrome: a multicenter prospective observational study. Meier ME; Hagelstein-Rotman M; van de Ven AC; Van der Geest ICM; Donker O; Pichardo SEC; Hissink Muller PCE; van der Meeren SW; Dorleijn DMJ; Winter EM; van de Sande MAJ; Appelman-Dijkstra NM Orphanet J Rare Dis; 2022 Dec; 17(1):439. PubMed ID: 36528764 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune-Albright Syndrome. Tucker-Bartley A; Selen DJ; Golden E; van Gool R; Ebb D; Mannstadt M; Upadhyay J Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768871 [TBL] [Abstract][Full Text] [Related]
10. The pathology of fibrous dysplasia and the McCune-Albright syndrome. Riminucci M; Robey PG; Bianco P Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():401-11. PubMed ID: 17982387 [TBL] [Abstract][Full Text] [Related]
12. Identification of GNAS Variants in Circulating Cell-Free DNA from Patients with Fibrous Dysplasia/McCune Albright Syndrome. Roszko KL; Guthrie L; Li X; Collins MT; de Castro LF; Boyce AM J Bone Miner Res; 2023 Mar; 38(3):443-450. PubMed ID: 36593655 [TBL] [Abstract][Full Text] [Related]
13. Fibrous dysplasia and McCune-Albright syndrome: imaging for positive and differential diagnoses, prognosis, and follow-up guidelines. Bousson V; Rey-Jouvin C; Laredo JD; Le Merrer M; Martin-Duverneuil N; Feydy A; Aubert S; Chapurlat R; Orcel P Eur J Radiol; 2014 Oct; 83(10):1828-42. PubMed ID: 25043984 [TBL] [Abstract][Full Text] [Related]
14. Increased Prevalence of Malignancies in Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS): Data from a National Referral Center and the Dutch National Pathology Registry (PALGA). Hagelstein-Rotman M; Meier ME; Majoor BCJ; Cleven AHG; Dijkstra PDS; Hamdy NAT; van de Sande MAJ; Dekkers OM; Appelman-Dijkstra NM Calcif Tissue Int; 2021 Mar; 108(3):346-353. PubMed ID: 33226445 [TBL] [Abstract][Full Text] [Related]
15. Craniofacial Fibrous Dysplasia: Clinical and Therapeutic Implications. Szymczuk V; Taylor J; Boyce AM Curr Osteoporos Rep; 2023 Apr; 21(2):147-153. PubMed ID: 36849642 [TBL] [Abstract][Full Text] [Related]
16. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome. Meier ME; Hagelstein-Rotman M; Streefland TCM; Winter EM; Bravenboer N; Appelman-Dijkstra NM Bone; 2023 Jun; 171():116744. PubMed ID: 36958543 [TBL] [Abstract][Full Text] [Related]
17. Choosing the Best Tissue and Technique to Detect Mosaicism in Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS). Vado Y; Manero-Azua A; Pereda A; Perez de Nanclares G Genes (Basel); 2024 Jan; 15(1):. PubMed ID: 38255009 [No Abstract] [Full Text] [Related]
18. Incidence and Prevalence of Fibrous Dysplasia/McCune-Albright Syndrome: A Nationwide Registry-Based Study in Denmark. Meier ME; Vágó E; Abrahamsen B; Dekkers OM; Horváth-Puhó E; Rejnmark L; Appelman-Dijkstra NM J Clin Endocrinol Metab; 2024 May; 109(6):1423-1432. PubMed ID: 38174586 [TBL] [Abstract][Full Text] [Related]
19. Phenotyping Pain in Patients With Fibrous Dysplasia/McCune-Albright Syndrome. Golden E; van der Heijden H; Ren B; Randall ET; Drubach LA; Shah N; Cay M; Ebb D; Kaban LB; Peacock ZS; Boyce AM; Mannstadt M; Upadhyay J J Clin Endocrinol Metab; 2024 Feb; 109(3):771-782. PubMed ID: 37804088 [TBL] [Abstract][Full Text] [Related]
20. Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. Bianco P; Riminucci M; Majolagbe A; Kuznetsov SA; Collins MT; Mankani MH; Corsi A; Bone HG; Wientroub S; Spiegel AM; Fisher LW; Robey PG J Bone Miner Res; 2000 Jan; 15(1):120-8. PubMed ID: 10646121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]